Nektar Therapeutics (NKTR) Could Be 71% Undervalued As Rezpegaldesleukin Data Extend Its Case
Nektar Therapeutics (NKTR) presented new clinical data for rezpegaldesleukin at the 2026 EADV Congress, showing long-term outcomes in atopic dermatitis and alopecia areata. Despite this, NKTR's stock has declined 41% in 1 month and 39% in 3 months, though it has a 3-year total shareholder return. Analysts suggest NKTR could be 71% undervalued at $144.40 per share, with a robust cash position extending its runway into 2027.
How this was made
The 30-second read
Why it matters
The trading debate is whether the new EADV data meaningfully improves late-stage success odds and timelines, or whether the stock’s prior selloff already reflects those expectations.
Market read
For traders, the actionable element is the incremental clinical-data narrative versus the market’s valuation skepticism and late-stage/funding risks.
What to watch
Conference data may not change near-term endpoints or regulatory timelines; the article also flags funding-cost risk, which can matter more than incremental efficacy signals for cash-burn biotechs.
Background
Simply Wall St frames NKTR’s rezpegaldesleukin story using conference-presented long-term outcomes and contrasts a “fair value” estimate versus current valuation metrics.
Ticker impact
Article says Nektar presented new rezpegaldesleukin clinical data at the 2026 EADV Congress, while NKTR shares have been choppy after a sharp selloff.
Likely near-term support from incremental clinical-data optimism, offset by skepticism given the large recent decline and valuation debate.
The piece highlights fresh rezpegaldesleukin long-term outcomes, yet frames the market reaction as already pricing in much of the upside and emphasizes late-stage stumbles and funding risk.
Market effects
Reinforces sentiment around dermatology-focused biotechs and the market’s willingness to re-rate on incremental late-stage data, but also highlights how valuation can cap upside.
Primarily US biotech sentiment, with no direct macro catalyst described.
Conference-driven read-through for international dermatology trial programs, but no cross-market policy or regulatory action cited.
Counterpoint
The bullish “71% undervalued” framing may be overstated if the market is already discounting probability-weighted late-stage outcomes and the high revenue multiple implied by the P/S comparison.
Key entities
- companyNektar Therapeutics
NKTR, presented new rezpegaldesleukin clinical data at the 2026 EADV Congress; shares have fallen sharply over recent months.
